Pro‐ and antiangiogenic therapies: current status and clinical implications. Issue 1 (7th August 2018)

• Record Type: Journal Article
• Authors: Rust, Ruslan; Gantner, Christina; Schwab, Martin E.
• Is Part Of: FASEB journal. Volume 33:Issue 1(2019)
• Page Start: 34
• Page End: 48
• Publication Date: 2018-08-07
• Subjects: vascularization -- vascular repair -- stroke -- retinopathy -- cancer; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.201800640RR
• Languages: English
• ISSNs: 0892-6638

Abstract

ABSTRACT: Blood vessels nurture every part of the human body. Consequently, abnormalities in the vasculature are closely associated with a variety of diseases, including cerebral stroke, heart disease, retinopathy, and cancer. Pro‐ or antiangiogenic therapies can influence these diseases by regulating the growth of new blood vessels from a pre‐existing vascular network or dampening excessive blood growth. However, clinical translation of these approaches is slow and challenging. In this review, we discuss recent preclinical approaches to regulate angiogenesis and their potential and risks in a clinical setting.—Rust, R., Gantner, C., Schwab, M. E. Pro‐ and antiangiogenic therapies: current status and clinical implications. FASEB J. 33, 34–48 (2019). www.fasebj.org